Q2 2026 saw 16% revenue growth and improved gross margins, with net loss narrowing to $15.7 million. Adjusted EBITDA turned positive, driven by strong international performance and cost efficiencies. Cash reserves of $440.6 million support ongoing expansion and clinical development.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.